NanoViricides will be presenting a review of the current programs that the comapany is developing for anti-viral therapeutics. It currently has four drugs in development that are commercially significant. This particular set of drugs attack HIV, the flu, various diseases that may afflict the eye and, the one most relevant for us folks, the herpes simplex virus. Yes, the one the virus that causes cold sores and genital herpes. This line of drugs, called nanoviricides are also being evaluated to test for effectiveness against ebola, dengue and rabies.
Among some of their more interesting projects include a drug called Flucide which has been proven effective in fighting H1N1 influenza in some animal tests for all kinds of influenza A strains. They are also anticipating it to be also effective against the bird flu and varius H1N1 virus.
About New York Biotechnology Association
NYBA is the leading advocate for advancing the success of the biotechnology industry in New York State and is its main representative to state policy makers, the media and communities. NYBA’s mission is to support the development and growth of New York’s biotechnology industry, and serve our members and the biotechnology community by providing a network for information exchange, shared services and collective action. NYBA’s membership comprises bioscience companies, world-class research institutions and related professional services. Under the banner of The Cures Start Here(R), the Association’s goal is to amplify the success New York has had and continues to have in discovering major medical advances and growing a vibrant biotech industry.